S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:UCBJF

UCB (UCBJF) Stock Price, News & Analysis

$119.90
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$119.90
$119.90
50-Day Range
$87.10
$122.00
52-Week Range
$69.70
$122.00
Volume
800 shs
Average Volume
203 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
UCBJF stock logo

About UCB Stock (OTCMKTS:UCBJF)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCBJF Stock Price History

UCBJF Stock News Headlines

UCB price target raised by EUR 13 at Barclays
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
UCB SA reports FY results
Stocks A-Z
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
UCB SA (UCBJF)
ZGNX Jan 2022 7.000 call
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
See More Headlines
Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:UCBJF
Employees
8,703
Year Founded
1928

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.27 billion
Cash Flow
$7.90 per share
Book Value
$50.52 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.55

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Jean-Christophe Tellier (Age 65)
    CEO & Executive Director
    Comp: $4.45M
  • Ms. Sandrine Dufour CFA (Age 58)
    Executive VP, CFO & Chief Corporate Development
  • Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)
    Executive Vice President of Supply & Technology Solutions
  • Dr. Dhavalkumar D. Patel M.D. (Age 63)
    Ph.D., Executive VP & Chief Scientific Officer
  • Ms. Denelle J. Waynick Johnson J.D. (Age 57)
    Executive VP & General Counsel
  • Mr. Jean-Luc Fleurial (Age 59)
    Executive VP & Chief Human Resources Officer
  • Prof. Iris Low-Friedrich (Age 64)
    Executive VP & Chief Medical Officer
  • Mr. Emmanuel Caeymaex (Age 55)
    Executive VP of Immunology Solutions & Head of US
  • Ms. Caroline Vancoillie
    Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions
  • Antje Witte
    Head of Investor Relations

UCBJF Stock Analysis - Frequently Asked Questions

Should I buy or sell UCB stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UCBJF shares.
View UCBJF analyst ratings
or view top-rated stocks.

How have UCBJF shares performed in 2024?

UCB's stock was trading at $87.10 at the beginning of the year. Since then, UCBJF stock has increased by 37.7% and is now trading at $119.90.
View the best growth stocks for 2024 here
.

How do I buy shares of UCB?

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:UCBJF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners